Sirnaomics Ltd. (HK:2257) has released an update.
Sirnaomics Ltd. has successfully completed a Phase I clinical trial for their RNAi therapeutic, STP707, demonstrating a strong safety profile and sustained disease control in treating pancreatic cancer patients. The study, which included 50 participants across 11 U.S. oncology clinics, showed promising results, particularly for 11 patients with pancreatic cancer, with no significant treatment-related adverse events reported. Investors are however cautioned by the company as the successful marketing of STP707 is not guaranteed.
For further insights into HK:2257 stock, check out TipRanks’ Stock Analysis page.
